**Supplementary Table S3.** Origin and characteristics of human MM cell lines.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| UP | Histotype | Gender | Age | Asbestos exposure | First line | Second line treatment | TTP | OS |
| 1 | Epithelioid | M | 74 | Unknown | Carbo+Pem | No | 7 | 11 |
| 2 | Epithelioid | F | 58 | Yes | Carbo+Pem | Pem | 6 | 13 |
| 3 | Epithelioid | M | 76 | Unknown | CisPt+Pem | No | 3 | 8 |
| 4 | Epithelioid | M | 68 | Yes | Carbo+Pem | Pem | 4 | 9 |
| 5 | Epithelioid | F | 84 | Yes | CisPt+Pem | No | 7 | 8 |
| 6 | Sarcomatoid | M | 80 | Yes | Carbo+Pem | Trabectedin | 3 | 5 |
| 7 | Sarcomatoid | F | 78 | Unknown | Pem | No | 4 | 6 |
| 8 | Sarcomatoid | M | 69 | Yes | Carbo+Pem | Trabectedin | 7 | 10 |
| 9 | Sarcomatoid | F | 74 | Unknown | Carbo+Pem | No | 5 | 7 |
| 10 | Sarcomatoid | M | 78 | Yes | Carbo+Pem | Trabectedin | 4 | 9 |

UP: unknown patient;M: male; F: female; Carbo: carboplatin; Pem: pemetrexed; CisPt: cisplatin; TTP: time to progression; OS: overall survival.